two isoforms, aCGRP and PCGRP, have been described. T h e use of C-terminal fragments of CGRP peptide, such as human aCGRP-(8-37), has led to the pharmacological subdivision of CGRP receptors into CGRP-1 [high potency for binding of human aCGRP-(8-37)] and CGRP-2 (lower potency) receptors. We have recently developed BIBN4096BS, the first non-peptide CGRP antagonist, which has sub-nanomolar affinity for primate CGRP receptors. T h e use of BIBN4096BS has led to the discovery of further functional CGRP receptor heterogeneity in rat tissues. T o further exploit BIBN4096BS as a pharmacological tool, we used BIBN4096BS in
Introduction
Calcitonin-gene-related peptide (CGRP) is a 37-amino-acid peptide that is expressed by neurons and endocrine cells in various tissues. Two discrete isoforms have been described : aCGRP, which is produced by alternative splicing of a calcitonin gene transcript, and PCGRP, the product of a separate gene [1, 2] . T h e two transcripts are highly similar, differing by three and one amino acids in human and rat respectively [3] . For both CGRP isoforms, potent vasodilatory activity has been demonstrated both in vitro and in vivo [4] . T h e vasodilatory activity of CGRP has recently gained importance in migraine pathogenesis [S] . At least two receptor types, CGRP-1 and CGRP-2, have been proposed from functional pharmacological experiments relying on differing affinities for the synthetic linear agonist [ C~S ( E~)~. ' ]~-C G R P~ (where h denotes human) and the peptidic antagonist h-aCGRP-(8-37) [6] . CGRP-1 receptors are characterized by a high affinity for h-aCGRP-(8-37), and CGRP-2 receptors are characterized by a high affinity for [ C~S ( E~) ' .~]~-C G R P~ and a low affinity for h-aCGRP-(8-37) [7] . In addition, there seems to be a tissue-specific distribution of CGRP-1 and CGRP-2 receptors, with CGRP-1 receptors being found in rat atrium, while CGRP-2 receptors are present in guinea pig vas deferens [8] .
Notwithstanding the apparent pharmacologically distinct functional CGRP receptor types, molecular correlates for discrete CGRP receptor types are still lacking. Functional CGRP receptors represent a multi-protein entity composed of at least three discrete proteins, i.e. the seventransmembrane receptor calcitonin-receptor-like receptor (CRLR), receptor-activity-modifying protein 1 (RAMPl) , and the cytoplasmic receptor component protein (RCP) [9-111. Different RAMPS have been cloned, and, depending on the association of the CRLR with a discrete RAMP, varying binding affinities of CGRP and adrenomedullin have been described [7] . Together, functional and molecular data could imply the presence 469 of discrete CGRP receptor subtypes [7] . However, so far the functional properties of CGRP receptors found in vivo or in tissues are not easily extrapolated from the function of the recombinant CRLR-RAMPI-RCP receptor complex [12] .
CGRP receptor antagonists
Few potent CGRP receptor antagonists suitable as pharmacological tools have been identified so far. T h e first non-peptide CGRP antagonist, , is a potent functional antagonist (pK, > 10) of CGRP-mediated CAMP formation in SK-N-MC cells [13] and human brain microvascular and astroglial cells [14] , and of CGRP-induced vasodilatation in human temporal arteries [15] ; it also potently blocks neurogenic vasodilatation in the marmoset [13] . While BIBN4096BS is selective for primate versus nonprimate CGRP receptors [13] , the affinity at rodent CGRP receptors is still in the low nanomolar range [16] . Interestingly, it was recently suggested that the species selectivity of BIBN4096BS may be determined by the RAMPl rather than the CRLR domain of the CGRP receptor [17] .
Further tools have been identified, such as the small-molecule antagonist SB-273779 [18] and the BIBN4096BS-related molecule BIBP4352BS (' compound 1 ') [ 191. However, the usefulness of these molecules is hampered by either their irreversible binding nature (SB-273779) and/or the relatively low potency (pKi values of < 7).
Use of BIBN4096BS as a pharmacological tool
We reported previously that BIBN4096BS discriminates between two pharmacologically distinct CGRP receptor types in rat vas deferens, presenting evidence for functional receptor heterogeneity in this particular tissue [20] . Therefore BIBN4096BS appears to be a valuable pharmacological tool to gain new insights into CGRP receptor heterogeneity. It has been demonstrated previously in guinea pig basilar artery, rat aorta and pig coronary artery that aCGRP-induced relaxation is blocked effectively by the antagonist h-aCGRP-(8-37), while the equally potent dilatory response to PCGRP is less potently antagonized [21, 22] h-aCGRP-(8-37)]. In the following we present data on the use of BIBN4096BS as a pharmacological tool to dissect CGRP receptor types involved in the vasodilatory response to different CGRP agonists in pig coronary and basilar arteries.
T o demonstrate an endothelium-independent dilation response in our test system, endothelium-intact and -denuded vessel rings were compared employing h-aCGRP as a vasodilator of prostaglandin F,, (PGF,,)-precontracted endothelium-intact and -denuded artery rings. No significant differences in sensitivity and maximal response to h-aCGRP were observed (results not shown), indicating the induction of an endothelium-independent vasodilatory response, in agreement with previous work [23, 24] .
T o evaluate agonist potency in small-and large-diameter pig left anterior descending (LAD) coronary arteries, discrete CGRP family members were tested. In both preparations, CGRP agonists induced concentration-dependent relaxation of PGF,,-precontracted pig LAD coronary vessels, with a l0Oo/, maximum response of the PGF,,-induced precontraction (Table 1) . A comparison of the potency of CGRP-receptor agonists in small-and large-diameter LAD coronary artery rings demonstrates an almost 10-fold decrease with increased vessel diameter ( Table 1 ). Similar observations were reported for a-and P-CGRP [24] in pig coronary artery and human lenticulostriate arteries [25] , suggesting a higher sensitivity of small-diameter vessels compared with larger ones with regard to a CGRP-induced vasodilatory response. Differential responses in large-and small-diameter coronary arteries to certain other vasodilators have been demonstrated. Nitrates, for example, tend to dilate conductive vessels and cause only a small increase in flow, whereas dipyridamole and adenosine increase coronary flow without changing large-vessel calibre [26, 27] . In addition, there is evidence for a differential distribution of adrenoceptor subtypes along the length of coronary arteries, with vasoconstrictor a,-adrenoceptors being more prevalent in largediameter coronary arteries and vasodilator /?,-adrenoceptors being located in small-calibre arteries [28] . However, the mechanism of differential responsiveness to CGRP seen in the two regions of the pig LAD coronary artery might be explained on the basis of different densities of CGRP receptors in this artery. In this respect, it was reported that large-and small-diameter human lenticulostriate arteries have similar levels of CRLR mRNA, whereas the amounts of RAMP1/2 mRNAs tend to be greater in largediameter arteries [25] , the significance of which has to be evaluated. Together, however, the agonist studies present no evidence for functional receptor heterogeneity.
T o characterize further the putative CGRP receptor heterogeneity, the antagonistic effect of BIBN4096BS in respect to vessel size was studied. A comparison of the potency of BIBN4096BS in aCGRP-compared with PCGRP-induced coronary vessel relaxation demonstrates an almost 10-fold more potent antagonistic effect in aCGRP assays. However, the calculated apparent pK, values of BIBN4096BS revealed no difference between values obtained in small-and largediameter vessels (Figure 1 ; Table 2 ). This is in line with one previous observation [25] using h-aCGRP-(8-37) : no difference in antagonistic potency on comparing small-and large-diameter Lessons from the Type II Family of G-Protein-Coupled Recepton human cerebral arteries was found. However, vessels by BIBN4096BS suggests that the difanother previous report showed a higher potency ferential vasodilator profile of CGRP in small-and of aCGRP-(8-37) in small-diameter pig coronary large-diameter rings from pig LAD coronary artery compared with large-diameter rings [24] . artery cannot be explained by different CGRP T h e lack of differentiation between small and large receptor subtypes. T o analyse further BIBN4096BS antagonism of a-and P-CGRP, we used another distinct vessel preparation, the cerebral arteria basilaris. Confirming the observations made in LAD coronary artery assays, the calculated apparent BIBN-4096BS pK, values obtained for a-and P-CGRP differed by more than 10-fold ( Figure 1 ; Table 2 ). This underlines the existence of discrete receptor systems for a-and P-CGRP, not only in coronary but also in cerebral vessels.
CGRP receptor heterogeneity
T o summarize, it can be stated that there is a receptor for aCGRP in pig coronary arteries and basilar arteries that is blocked by BIBN4096BS with high potency. There is a similar receptor type in rat atrium, in that the effects of aCGRP are effectively blocked by BIBN4096BS in this tissue [20] . Since the pK, values of BIBN4096BS for aCGRP in the pig LAD coronary artery resemble those in rat left atrium, one may assume that aCGRP probably acts through CGRP-1 -like receptors in the pig LAD coronary artery. The pK, values for BIBN4096BS against PCGRP in the pig LAD coronary artery and basilar arteries were between 6.6 and 7.0, similar to those found for the CGRP-2 receptor in vas deferens [20] . It is as yet unclear whether the differential functional blockade of a-and 8-CGRP by BIBN4096BS can be explained by a differential action on CGRP-I/ CGRP-2 receptors.
T o probe for the existence of the molecular components of the CGRP receptor, coronal vessels were studied for the presence of transcripts for CRLR, RAMPI-3 and RCP by reverse transcriptase-PCR. We found strong expression of RAMPI, a weak signal for RAMP2 and no RAMP3 expression, with both CRLR and RCP transcripts also being present (results not shown). Thus all components required for the formation of functional CGRP-1 (RAMP1) and adrenomedullin (RAMP2) receptors are present in this tissue.
T h e existence of different CGRP receptors has been proposed based on various pharmacological and functional studies [6, 21, 22 ]. Here we provide further evidence for the existence of discrete CGRP receptor subtypes, based on the use of BIBN4096BS. Our studies have also addressed the potential existence of adrenomedullin receptors in coronary vessels. In our hands, BIB-N4096BS has no affinity in vitro for adrenomedullin binding sites, either in tissue or at the 
Conclusions
In conclusion, different CGRP receptor subtypes seem to be present in both the pig LAD coronary artery and the cerebral basilar artery. The molecular nature of the pharmacologically distinct CGRP receptor subtypes needs to be explored further [12] . An integrated approach is required to bring together molecular biology data with a clear functional characterization of the ' recombinant' CGRP and adrenomedullin receptors, in addition to a thorough investigation of CGRP receptor subtypes within one given species.
